Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Spain sets up human TSE (transmissible spongiform encephalopathy) register:

This article was originally published in Clinica

Executive Summary

Spain has set up a transmissible spongiform encephalopathies (TSE) register, incorporating the current Creutzfeldt-Jakob disease (CJD) register. The measure will see the compulsory recording of all cases of human TSE, ranging from variant CJD to rarer related conditions such as Gerstmann Straussler-Scheinker syndrome. Until now, there has been a legal requirement to report only classical CJD cases. The new register will be compiled regionally, as part of the national epidemiological surveillance network, and in accordance with EU requirements. The government has expressed growing concern at the need for better information on TSE diagnosis and prevention.

You may also be interested in...

Coronavirus Update: UK Calls For COVID-19 Patients To Join Trials

Commission’s One-Year MDR Delay Text Contains EU-Wide Derogation Proposals Too

The race is now on to get formal adoption of European Commission proposal postponing the MDR by one year and allowing more devices on the market more quickly. But potential hurdles are in the way as experts advise caution.

Australia Relaxes Competition Rules To Facilitate Coronavirus Response

Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts